Olezarsen proves effectiveness in severe hypertriglyceridemia, with Nicholas Marston, MD |

Marston are the first tests and help to reduce the risk of rapid fire.

Olezarsen Demonstrates Efficacy in Severe Hypertriglyceridemia, with Nicholas Marston, MD

Marston discusses the CORE and CORE 2 trials, highlighting the success of olesarsen in lowering fasting triglycerides.

The phase 3 CORE and CORE2 trials demonstrated the efficacy of olegersen in patients

Data from both trials are presented in

"At this point, we don't see a clinical context here, just an imaging result," Marston told HCPLive."We'll be tracking that over time in the open-label extension to see if that's something that plateaus. I think eventually it's going to be something that we learn more about, and we'll keep an eye on that."

The oligonense oligonucleotide in the ShTG treatment test was designed to reduce Apoc-III production.This protein controls the metabolism of triglycerides in the blood, the elimination of triglycerides, and the increase of the liver in triglycerides.Although approved for chylomicronemia syndrome in the US and EU, safety and efficacy have not been established for ShTG.1

C Core and Core2 each included CHEMI 72A and Cor-TMI 72B in a double-blind, randomized, randomized trial.The primary endpoint for both trials was the change from baseline to baseline at 6 months.The trading results from the secondary doubt are basically three months and the change in the bottom line when changing to Aop-cii (percent change) rub, residual shellylol and 6 to 12 months.KDL-C levels are not included.In addition, the examiner noted the presence of a thick gastric border in both courts.

A total of 1,063 patients with SHTG were generally included, including 617 in the Core trial and 446 in the Core2 trial.They were then randomly attacked 1: 1 to either Olizarsars 50 mg, Olizarsen 80 mg, or Plebo, all donated monthly for 12 months.Both tests included MRI Sub-study, assessing changes in hepatic fat after a year.The age in both trials was 54 years, and the average triglyceride level was 796 mg/dl.1

At 6 months, Marston and colleagues found a mean square change in triglycerides olezarsen 80 and -7200 arm A arm 80 in that case.By comparison, the mean triglyceride level change in Core2 was 50.2% points in Olezarsen 80 mg.2

The team also compared triglycerides, apoc-III, APOC-III, residual cholesterol and non-HDL-C, non-HDL-C and non-HDL-C, non-HDL-C in the Alexena arms.Acute pancreatitis was less with both Ilexen and Oyezarsen (mean odds ratio 0.15; 95%), 0.05 to 0.4, 0.05 to 0.4;001).Increases in liver enzyme levels and thrombocytopenia were observed after a dose of 80 mg of weapon and a dose-dependent increase in the vedamary fraction 2

Finally, Marchon discusses the potential applications of Oxturma.

"I think it could be seen as an add-on, but I think for high-risk patients who already have pancreatitis, we don't want to delay them getting enzaren," Marston said.

Mantton N, Bergmark B, Alexander V, et al.Olezarsen in patients with severe Hypertriglyceridemia: The CreD-Tini 72A and Cor2-Tini 722 Proficand.It appears in the American House Wites Desassion neciectional Serversions 2025. New orleans, Louisiana.November 8-10, 2025.

Marston NA, Bergmark BA, Alexander VJ, et al.Olesarsen for the treatment of severe hypertriglyceridemia and risk of pancreatitis.New England Journal of Medicine.

Join thousands of doctors staying up-to-date on the latest treatments, trial data and information experts - sign up today.